Showing results (221-230 of 5,439) with videos related to
Sort By:
Pageof 544
Bulletin Du Cancer|February 21, 2004
[What's new in the treatment of cancer pain?]Mario Di Palma, Philippe Poulain, Evelyne PichardBulletin Du Cancer|November 22, 2021
[Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)]Cécile Pochon, Corinne Courbon, Jacques-Olivier Bay, et al.Bulletin Du Cancer|January 17, 2022
[Supportive care in pediatric oncology: Considering children and AYA's special needs]Marilyne Poirée, Mylène Duplan, Maïna Letort-Bertrand, et al.Bulletin Du Cancer|September 10, 2022
[Expertise for management of immune-related adverse events in cancer therapy: Mapping of French practicing]Valentin Coudert, Nicolas Penel, Marie Cécile Le Deley, et al.Bulletin Du Cancer|December 14, 2021
[Normal organoids and their applications in cancer research]Frederic Delom, Valérie Le Morvan, Jacques Robert, et al.Bulletin Du Cancer|December 13, 2021
[Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, et al.Bulletin Du Cancer|December 18, 2021
CAR-T cell: Toxicities issues: Mechanisms and clinical managementFlorent Wallet, Pierre Sesques, Perrine Devic, et al.Bulletin Du Cancer|December 18, 2021
[Bispecific antibodies: An old story with a bright future… with CAR-T cells!]Clémence Riffard, Jean-Luc TeillaudBulletin Du Cancer|December 18, 2021
CAR T-cells in acute lymphoblastic leukemia: Current resultsMarie Emilie Dourthe, André BaruchelBulletin Du Cancer|December 18, 2021
[CAR-T cells immunotherapy in multiple myeloma: Present and future]Benoît Ferment, Bertrand ArnulfPageof 544